Recombinant Human Oligodendrocyte Transcription Factor 2 (OLIG2) Protein (His-SUMO)

Name: Recombinant Human Oligodendrocyte Transcription Factor 2 (OLIG2) Protein (His-SUMO)
Brand: Beta LifeScience
SKU: BLC-09517P
Availability: InStock

Greater than 90% as determined by SDS-PAGE.

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Product Overview

Description	Recombinant Human Oligodendrocyte Transcription Factor 2 (OLIG2) Protein (His-SUMO) is produced by our E.coli expression system. This is a full length protein.
Purity	Greater than 90% as determined by SDS-PAGE.
Uniprotkb	Q13516
Target Symbol	OLIG2
Synonyms	Basic domain helix loop helix protein class B 1; Basic helix loop helix protein class B 1; BHLHB; bHLHB1; bHLHe19; Class B basic helix loop helix protein 1; Class B basic helix-loop-helix protein 1; class E basic helix loop helix protein 19; Class E basic helix-loop-helix protein 19; Human protein kinase C binding protein RACK17; Olig2; OLIG2_HUMAN; Oligo2; Oligodendrocyte lineage transcription factor 2; Oligodendrocyte specific bHLH transcription factor 2; Oligodendrocyte transcription factor 2; OTTHUMP00000067569; OTTHUMP00000067570; PRKCBP2; Protein kinase C binding protein 2; Protein kinase C binding protein RACK17; Protein kinase C-binding protein 2; Protein kinase C-binding protein RACK17; RACK17
Species	Homo sapiens (Human)
Expression System	E.coli
Tag	N-6His-SUMO
Target Protein Sequence	MDSDASLVSSRPSSPEPDDLFLPARSKGSSGSAFTGGTVSSSTPSDCPPELSAELRGAMGSAGAHPGDKLGGSGFKSSSSSTSSSTSSAAASSTKKDKKQMTEPELQQLRLKINSRERKRMHDLNIAMDGLREVMPYAHGPSVRKLSKIATLLLARNYILMLTNSLEEMKRLVSEIYGGHHAGFHPSACGGLAHSAPLPAATAHPAAAAHAAHHPAVHHPILPPAAAAAAAAAAAAAVSSASLPGSGLPSVGSIRPPHGLLKSPSAAAAAPLGGGGGGSGASGGFQHWGGMPCPCSMCQVPPPHHHVSAMGAGSLPRLTSDAK
Expression Range	1-323aa
Protein Length	Full Length
Mol. Weight	48.4kDa
Research Area	Epigenetics And Nuclear Signaling
Form	Liquid or Lyophilized powder
Buffer	Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution	Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	Required for oligodendrocyte and motor neuron specification in the spinal cord, as well as for the development of somatic motor neurons in the hindbrain. Functions together with ZNF488 to promote oligodendrocyte differentiation. Cooperates with OLIG1 to establish the pMN domain of the embryonic neural tube. Antagonist of V2 interneuron and of NKX2-2-induced V3 interneuron development.
Subcellular Location	Nucleus. Cytoplasm.
Database References	HGNC: 9398 OMIM: 606386 KEGG: hsa:10215 STRING: 9606.ENSP00000331040 UniGene: Hs.176977
Associated Diseases	A chromosomal aberration involving OLIG2 may be a cause of a form of T-cell acute lymphoblastic leukemia (T-ALL). Translocation t(14;21)(q11.2;q22) with TCRA.
Tissue Specificity	Expressed in the brain, in oligodendrocytes. Strongly expressed in oligodendrogliomas, while expression is weak to moderate in astrocytomas. Expression in glioblastomas highly variable.

Gene Functions References

indicate Olig2 as an onco-requisite factor in diffuse intrinsic pontine glioma PMID: 28339768
OLIG2 immunoreactivity was observed in GABAergic cells of the proliferative zones of the MGE and septum, but not necessarily co-expressed with NKX2.1, and OLIG2 expression was also extensively seen in the LGE, CGE, and cortex PMID: 27905023
Data suggest positive feedback loops including oligodendrocyte transcription factor 2 (OLIG2): loops of epigenetic regulation. PMID: 27447975
Data show that oligodendrocyte transcription factor 2 (OLIG2) is epigenetically regulated via DNA methylation and expressed in a subset of AML patients. PMID: 28760688
Ectopic expression of phosphomimetic Olig2 is sufficient to block TGF-beta2-mediated invasion. PMID: 27396340
phosphorylation of the motif itself serves as a template to prime phosphorylation of additional serines and creates a highly charged "acid blob" in the amino terminus of Olig2. PMID: 28355568
Olig2 was expressed in cord blood eosinophils on d 24, when cord blood eosinophils are considered fully differentiated, but no earlier. It was also expressed in human peripheral-blood eosinophils but not neutrophils, monocytes, lymphocytes, or cord blood mast cells. Many genes, including eosinophil surface molecules, were up-regulated along with OLIG2. OLIG2 shRNA or siRNA downregulated SIGLEC-8 mRNA and protein. PMID: 27154355
Data indicate that transcription factors Sox10 and Olig2 play key roles in oligodendrocytes (OLs) specification. PMID: 27785726
Olig2 expressions were successfully detected in 12 (15.58%) of 77 SVZ type II Glioblastomas (GBs) and 16 (21.3%) of 75 SVZ type III GBs. PMID: 27179219
Olig2 was positive in 5 out of 44 ependymomas (11%) and 50 out of 54 (93%) non-ependymal tumors PMID: 26287936
The present study is the first to verify the associations of SNPs rs762178, rs1059004, and rs9653711 of the OLIG2 gene with OCD in a Chinese Han population. Thus, OLIG2 might serve as a potential target for OCD treatment PMID: 26271930
The results demonstrate that the expression of Olig2 in dental pulp stem cells reduces the expression of stem cell markers and induces the development of oligodendrocyte progenitors. PMID: 25966902
High Olig2 expression is associated with oligodendrogliomas. PMID: 25085214
OLIG2 is the most specific GSC marker. PMID: 25384509
Our study suggests that CGT expression is controlled by balanced expression of the negative modulator OLIG2 and positive regulator Nkx2.2, providing new insights into how expression of GalCer is tightly regulated in cell-type- and stage-specific manners. PMID: 24821492
Authors investigated the role of Pten in these two critical cellular compartments in adult and developing brains using methods for activation or suppression of PI3K signaling in glial and neuronal progenitors expressing Olig2. PMID: 24395742
LGR5 expression may be functionally correlated with the neurogenic competence, and be regulated by OLIG2 in stem-like cells in glioblastoma. PMID: 23793848
We found that the risk allele OLIG2 (A) was associated with reduced white matter integrity in the corona radiata bilaterally PMID: 22505278
Olig2-positive cells in glioneuronal tumors, and some of them also exhibited neuronal features PMID: 23025580
Report role of OLIG2 immunostaining pattern in diagnosing rare and glioblastoma variants. PMID: 23041832
This study review OLIG2 have developmental functions in patterning, neuron subtype specification and the formation of oligodendrocytes and play the role in the postnatal brain during repair processes and in neurological disease states. PMID: 23165259
OLIG2 over-expression inhibits neural progenitor proliferation through changes in potassium channel activity, thereby contributing to the reduced neuronal numbers and brain size in DS. PMID: 22343408
Nogo-A is more useful and specific than Olig-2 in differentiating oligodendrogliomas from other gliomas. PMID: 21835431
Olig2 expression is restricted to isolation and during membrane production of regenerating oligodendrocyte cultures isolated from white matter of medically intractable epilepsy patients. PMID: 21446039
The Olig2 can induce desired neuronal lineages from most expressing neural progenitor cells by a mechanism resembling developmental binary cell-fate switching. PMID: 21624811
suggesting that OLIG2 function in pediatric gliomas is cell lineage dependent PMID: 21193945
analysis of conserved and non-conserved functional elements at the Olig1 and Olig2 locus PMID: 21206754
1p19q whole loss was also significantly associated with Olig2 overexpression, but was never observed in tumors overexpressing p53 protein in oligodendroglial tumors PMID: 20081802
Analysis of 180 primary, metastatic, and non-neural human tumors shows OLIG2 is highly expressed in all diffuse gliomas. Immunohistochemistry and microarray analyses demonstrate higher OLIG2 in anaplastic oligodendrogliomas versus glioblastomas. PMID: 15198128
Overexpression of OLIG2 was not only found in oligodendroglioma samples and normal neural tissue but also in a wide spectrum of malignant cell lines including leukemia, non-small cell lung carcinoma, melanoma, and breast cancer cell lines. PMID: 16103065
Olig1 and Olig2 transcription factors in the human central nervous system are important not only for differentiation of the oligodendrocyte lineage, but they may also have a role in neural cell specification. PMID: 16267213
Transcriptional regulation of transgenic Olig2 is involved in segregation of motoneuron precursor neuroblasts in the developing mouse spinal cord. PMID: 16469306
A novel function of OLIG2 is to suppress glial tumor cell growth via cyclin-dependent kinase inhibitor p27. PMID: 16554441
Findings show a general requirement for Olig2 function in glial cell development and highlight further roles for Olig transcription factors in neural progenitor cells. PMID: 16682644
Data provide strong convergent evidence that variation in OLIG2 confers susceptibility to schizophrenia alone and as part of a network of genes implicated in oligodendrocyte function. PMID: 16891421
Mutations in OLIG1 and OLIG2 are not likely to be associated with this subgroup of hypomyelinating disorders. PMID: 17171653
OLIG2 expression was predominant over ID2 expression in oligodendroglial tumors, while ID2 expression was predominant over OLIG2 expression in astrocytic tumors. PMID: 17431671
No significan correlation was found between proliferation index in pilocytic astrocytomas and Olig-2 expression. PMID: 17690840
IL-13Ralpha2 and Olig2 have been identified and confirmed to be interesting candidate genes whose differential expression likely plays a role in malignant progression of astrocytomas PMID: 17917751
absence of OLIG2 mutation in three PMLD patients presenting with a phenotype characterized by severe hypomyelination and motor neuron dysfunction PMID: 17918228
The SNP rs762178 in OLIG2 seems to be a potential candidate in altering risk for schizophrenia in the Chinese Han population. PMID: 17934761
OLIG2 suppresses the motile phenotype of glioblastoma cells by activating RhoA. PMID: 17951409
We found that genetic polymorphisms in CNP (rs2070106) and OLIG2 (rs1059004 and PMID: 17964117
analysis of Olig2 immunohistochemistry in microcystic areas might therefore be useful for the differential diagnosis of pilocytic astrocytoma and diffuse astrocytomas . PMID: 18312545
Olig2-immunohistochemistry is useful and potentially more reliable than the epithelial membrane antigen-immunohistochemistry for the diagnosis of ependymoma PMID: 18552083
Olig2-induced neural stem cell differentiation involves downregulation of Wnt pathway. PMID: 19093005
Significant evidence for association of psychotic symptoms within cases was identified for two SNPs, rs762237 and rs2834072. PMID: 19477230
transplantation of human neural stem cells genetically modified to express Olig2 transcription factor improved locomotor recovery and enhanced myelination in a rat contusive spinal cord injury model. PMID: 19772605

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.